Obsidian Therapeutics, Inc. Common Stock (OBX) - Net Assets
Based on the latest financial reports, Obsidian Therapeutics, Inc. Common Stock (OBX) has net assets worth $-276.20 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($70.14 Million) and total liabilities ($346.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Obsidian Therapeutics, Inc. Common Stock (OBX) net asset quality to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-276.20 Million |
| % of Total Assets | -393.8% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Obsidian Therapeutics, Inc. Common Stock - Net Assets Trend (2024–2025)
This chart illustrates how Obsidian Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see OBX stock market capitalisation.
Annual Net Assets for Obsidian Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual net assets of Obsidian Therapeutics, Inc. Common Stock from 2024 to 2025. Also explore OBX net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-266.04 Million | -52.52% |
| 2024-12-31 | $-174.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Obsidian Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10060700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $29.90 Million | % |
| Total Equity | $-266.04 Million | 100.00% |
Obsidian Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Obsidian Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Sanwei Rubber Item Co
SHG:603033
|
$1.05 Billion |
|
Dorian LPG Ltd
NYSE:LPG
|
$1.05 Billion |
|
Yutong Optical
SHE:300790
|
$1.05 Billion |
|
SeAH Bestee
KO:001430
|
$1.05 Billion |
|
Yantai Changyu Pioneer Wine Co Ltd
SHE:000869
|
$1.05 Billion |
|
Suofeiya Home Collection Co Ltd
SHE:002572
|
$1.05 Billion |
|
Mercantile Bank Corporation
NASDAQ:MBWM
|
$1.05 Billion |
|
Safety Insurance Group Inc
NASDAQ:SAFT
|
$1.05 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Obsidian Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -174,431,000 to -266,037,000, a change of -91,606,000.
- Net loss of 100,607,000 reduced equity.
- Other factors increased equity by 9,001,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-100.61 Million | -37.82% |
| Other Changes | $9.00 Million | +3.38% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Obsidian Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $-2.83 | $17.00 | x |
| 2025-12-31 | $-4.32 | $17.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Obsidian Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-65.67 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-74.00 Million |
Industry Comparison
This section compares Obsidian Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Obsidian Therapeutics, Inc. Common Stock (OBX) | $-276.20 Million | 0.00% | N/A | $1.05 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Obsidian Therapeutics, Inc. Common Stock
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform de… Read more